The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2023 | GALACTIC: evaluating obinutuzumab consolidation post-chemoimmunotherapy in CLL
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, gives an overview of the results obtained in the Phase II/III GALACTIC study (CRUK/11/040), which evaluated the use of obinutuzumab as consolidation therapy in patients with chronic lymphocytic leukemia (CLL) following chemoimmunotherapy. Results demonstrated that the outcomes of patients receiving obinutuzumab consolidation were similar to those who became measurable residual disease (MRD) negative after chemoimmunotherapy. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
